Our roundtable found three biotechs with a nice cash cushion.
Compare NVTA Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
News & Analysis: Invitae
The medical genetics company reported disappointing Q1 results.
NVTA earnings call for the period ending March 31, 2022.
Invitae is a leading genetic testing company that's been public since 2015. Why has the stock done so poorly?
The molecular diagnostics company is bouncing back from its two-year low.
NVTA earnings call for the period ending December 31, 2021.
Before buying shares, investors need to think about Invitae's most significant red flag.
The big news from Invitae's Q3 update was a worsening bottom line.
Analyst price targets for three top growth stocks suggest big gains just up ahead.
NVTA earnings call for the period ending September 30, 2021.